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Abstract The transposon Tn5 carries a gene, ble, which confers
resistance to bleomycin (Bm) and gives a survival advantage to
its host cell. We found that the ble gene product, designated
BLMT, is a binding protein with a strong affinity for Bm.
BLMT quenched both the antibacterial and DNA-cleaving
activities of Bm, when incubated with the antibiotic. An electron
spin resonance spin-trapping analysis showed that BLMT
inhibits the generation of Bm-induced hydroxyl radical, by
trapping Bm but not the hydroxyl radical. Western blot analysis
using an anti-BLMT monoclonal antibody revealed that BLMT
is immunologically distinct from Bm-binding proteins from
Streptomyces verticillus, Staphylococcus aureus and Streptoal-
loteichus hindustanus. Escherichia coli, transformed with a
mutant ble having leucine instead of proline at N-terminal amino
acid position 7, lost resistance to Bm, although the cell
maintained the survival benefit. This suggests that the Bm
resistance mediated by ble is independent of its ability to give a
survival advantage to the host bacterium.
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1. Introduction
Bleomycin (Bm), produced by Streptomyces verticillus, is a
glycopeptide antibiotic which is clinically used in the treat-
ment of certain tumors [1]. The Bm-Fe(II) complex, in con-
junction with reducing agent and oxygen, causes nucleotide
sequence-speci¢c DNA cleavage [2]. A two-step mechanism
has been suggested for DNA cleavage, involving the interac-
tion of the bithiazole moiety of Bm into DNA followed by
decomposition of a labile Fe(II)-Bm-O2 complex to generate a
Fe(III)-Bm complex and either hydroxy or superoxide radicals
that can then degrade the DNA [2].
Bm-producing S. verticillus must be protected from the
lethal e¡ect of its own product. We have cloned and se-
quenced two independent genes, designated blmA and blmB,
encoding Bm resistance determinants from S. verticillus
ATCC 15003 [3]. The genes blmA and blmB were shown to
encode a Bm-binding protein and an N-acetyltransferase, re-
spectively [4,5]. Tallysomycin-producing Streptoalloteichus
hindustanus has a gene, designated Shble, encoding a protein
which binds to Bm [6,7].
Interestingly, although Bm has never been used as an anti-
bacterial agent, most strains of methicillin-resistant Staphylo-
coccus aureus (MRSA), clinically isolated in Hiroshima Uni-
versity Hospital, Japan, were resistant to the drug at a high
level. We have cloned and sequenced a Bm resistance gene,
designated blmS, from the chromosomal DNA of MRSA
strain B-26 [8,9]. The gene was identical to that located on
a staphylococcal plasmid pUB110. We have shown that
pUB110 was integrated into the chromosomal DNA with
the mediation of IS431mec [9]. We have found that the
blmS gene product, designated BLMS, is also a Bm-binding
protein [4].
A Bm resistance gene, ble, encoded on the transposon Tn5
[10,11], has been reported to confer a survival advantage to
Escherichia coli host cells [12,13]. Although it has been sug-
gested that this advantage to the bacterium might be mediated
via an induction of the DNA repair system, the contributory
mechanism to this repair system and physico-chemical proper-
ties of the ble gene product have not yet been determined.
The aim of the present study is to overproduce and char-
acterize the ble gene product, designated BLMT. This is the
¢rst puri¢cation of the Bm-binding protein. Moreover, this
paper reports on the successful generation of the anti-
BLMT monoclonal antibody, for the immunological charac-
terization among BLMT and other Bm-binding proteins. We
de¢ned the function of ble gene product by creating a mutant
ble protein lacking resistance to Bm.
2. Materials and methods
2.1. Bacterial strains and plasmid constructions
E. coli HB101 and plasmid pKKtrp [4] having the trp promoter
were used to overexpress ble. E. coli BMH71-18 mutS and plasmid
pUC18 were used for site-directed mutagenesis.
The plasmid pUC4KIXX [14], purchased from Pharmacia (Swe-
den), was used as a source of ble. The ble structural gene having
EcoRI and HindIII sites at the 5P- and 3P-adjacent regions, respec-
tively, was ampli¢ed by PCR using a sense 5P-GGGGGAATTCAT-
GACCGACCAAGCGACGCC-3P primer and an antisense 5P-GAA-
GAAGCTTTCATGAGATGCCTGCAAGCA-3P primer, and pUC4-
KIXX as the DNA template. The ampli¢ed ble was subcloned into the
EcoRI- and HindIII-digested pKKtrp to generate pKKblmT.
To create a mutant ble having leucine instead of proline at N-ter-
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minal position 7 by site-directed mutagenesis, the ampli¢ed ble was
subcloned into pUC18 digested with EcoRI and HindIII to generate
pUCblmT. The two oligonucleotides, 5P-CTTCCTTTTTCGATAT-
CATTGAAGCATTT-3P as a selection primer and 5P-GTGATGG-
CAGGTTCAGCGTCGCTTGGTCG-3P as a mutagenic primer,
were chemically synthesized and annealed to the template pUCblmT
which was denatured at 100‡C. The mutant DNA strand, synthesized
with T4 DNA polymerase, was introduced into E. coli BMH71-18
mutS. This mutagenic experiment was performed using Transformer
Site-Directed Mutagenesis Kit (Clontech, USA), according to the sup-
plier’s protocol based on the method described in [15]. The mutant ble
was cloned into pKKtrp to generate pKKblmTM.
2.2. Isolation of BLMT
E. coli HB101 harboring pKKblmT was grown in M9-casamino
acid medium [16] containing ampicillin 100 Wg/ml. At the exponential
phase of growth, 3-indoleacrylic acid (0.13 mM) was added to the
culture to induce the trp promoter and incubated for 24 h. The har-
vested cells, washed with 20 mM Tris-HCl (pH 7.6), were ground with
quartz sand and extracted with bu¡er A (20 mM Tris-HCl, pH 7.6, 30
mM NH4Cl, 10 mM Mg-acetate, 6 mM 2-mercaptoethanol, 5 mM
Mg-titriplex and 3.45 mM phenylmethylsulfonyl £uoride). The result-
ing supernatant £uid was collected by centrifugation at 18 000Ug for
20 min. Solid ammonium sulfate was added to the supernatant at 20%
saturation and the resulting precipitate was removed by centrifuga-
tion. BLMT was precipitated from the supernatant by addition of
ammonium sulfate at 40% saturation, dissolved in small volumes of
20 mM Tris-HCl (pH 7.6) and dialyzed against the same bu¡er. The
dialysate was subjected to a DEAE-Sepharose CL-6B column
(1.8U20 cm) equilibrated with the same bu¡er and eluted with 20
mM Tris-HCl (pH 7.6) bu¡er containing 0^1 M NaCl in a linear
concentration gradient. The fractions containing BLMT, concentrated
using ULTRACENT (Tosho, Japan), were ¢nally applied on a Se-
phadex G-75 super¢ne column (1.8U120 cm) to purify to homogene-
ity.
2.3. Measurement of molecular weight of BLMT
The molecular weight of BLMT was estimated by the gel ¢ltration
method using a Sephadex G-75 super¢ne column equilibrated with 25
mM Tris-HCl (pH 7.6) and 10 mM NaCl. Albumin (66.2 kDa), oval-
bumin (43 kDa), chymotrypsinogen (25.7 kDa) and RNase A (13.7
kDa) were used as the size marker proteins.
2.4. N-terminal amino acid sequence
The N-terminal amino acid sequence of BLMT was determined by
Edman degradation method using the auto-sequencer (Shimadzu, Ja-
pan).
2.5. Spin-trapping and ESR measurements
To make the 1:1 Fe(III)-Bm complex, 0.1 mM FeCl3 and Bm A2
sulfate were mixed in 50 mM Tris-HCl (pH 7.8). After the complex
was incubated together with 80 mM K-phenyl-N-tert-butylnitron
(PBN) as a spin trap reagent, the spin-trapping experiment was
started under atmospheric conditions by adding 2-mercaptoethanol
as a reductant. An aliquot of the reaction mixture was rapidly trans-
ferred into a quartz cell and analyzed for electron spin resonance
(ESR) at 298 K. Generation of radicals by the xanthine-xanthine
oxidase system was performed according to the method described
previously [17].
X-Band ESR spectra were recorded with a JES-FE-1X spectrometer
(JEOL, Japan) operating with 100 kHz magnetic ¢eld modulation.
The ESR conditions were as follows: frequency, 9.43 GHz; power,
8 mW; modulated amplitude, 0.8 Gauss; sweep time, 2 min; time
constant, 0.1 s.
2.6. Generation of anti-BLMT monoclonal antibody
The puri¢ed BLMT was used as an antigen and injected intraper-
itoneally to BALB/c mice. An anti-BLMT monoclonal antibody was
generated by the same method as described previously [4].
2.7. SDS-PAGE and Western blotting
The tricine-SDS-PAGE system [18] was employed for the resolution
of small proteins such as BLMT at 10% acrylamide concentration.
The proteins, separated by the system, were electrophoretically trans-
ferred onto a nitrocellulose membrane (Hybond-C super, Amersham,
UK) and detected by the anti-BLMT monoclonal antibody using Elite
ABC kit (Vectastain, USA).
2.8. Cell survival analysis
The cell survival assay was performed as described in [12]. E. coli
harboring a plasmid was grown in Erlenmeyer £asks with 40 ml
of Luria-Bertani (LB) medium [16] supplemented with ampicillin
200 Wg/ml and gently shaken at 37‡C. Portions of the culture were
collected at given periods and diluted appropriately. The cells, grown
on LB agar containing 200 Wg/ml ampicillin, were counted to deter-
mine the colony-forming units.
3. Results and discussion
3.1. Physico-chemical properties of the ble gene product
To characterize BLMT physico-chemically, we overex-
pressed ble under the control of the trp promoter and puri¢ed
the gene product to homogeneity. Its N-terminal ¢ve amino
acid sequence was MTDQA, identical with that deduced from
the nucleotide sequence of ble. This result indicates that the
N-terminal methionine is not processed in the same way as
BLMA and BLMS described in [4]. The molecular weight of
BLMT, deduced from its nucleotide sequence described in
[11], is 14 058 Da. However, the molecular weight of BLMT
estimated by a Sephadex G-75 column chromatography, was
about 34 kDa, suggesting that this protein is dimeric. The X-
ray crystallographic analysis of BLMA from S. verticillus
showed that the protein takes a dimer structure (submitted).
The isoelectric point of BLMT determined with PAGE con-
taining ampholytes (pH 3^5, Bio-Lyte, Bio-Rad, USA), was
4.5. This value is almost the same as the theoretical isoelectric
point (4.34) estimated from the deduced amino acid sequence,
clearly indicating that BLMT is also an acidic protein like
BLMA, BLMS and Shble protein. Even when incubated
with BLMT in the absence of co-factors, such as acetyl coen-
zyme A or ATP, Bm lost the ability to degrade DNA. In
addition, heat treatment at 100‡C for 20 min or digestion
with protease K (200 Wg/ml) of the BLMT/Bm complex re-
stored the DNA-cleaving activity of the antibiotic. These re-
sults suggest that BLMT protects against Bm-induced DNA
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Fig. 1. The electrophoretic migration pro¢le of the BLMT protein
pre-incubated with Bm. BLMT (8 Wg) was incubated with Bm (8
Wg) for 3 h at 16‡C and subjected to native PAGE containing 15%
acrylamide. Lanes 1 and 2, BLMT without and with Bm, respec-
tively.
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breakage, which occurs without covalent modi¢cation of the
drug, like BLMA [4]. Fig. 1 shows that BLMT migrated more
slowly on native PAGE when pre-incubated with Bm, than
without Bm.
The Fe(III)-Bm-oxygen system, in the presence of a reduc-
tant, or the Fe(II)-Bm-oxygen system without the reductant
produces potentially reactive free-radical species [19^22]. We
examined, using an ESR spin-trapping technique, whether
BLMT interferes with the production of hydroxyl radicals
by the Fe(III)-Bm system in the presence of 2-mercaptoetha-
nol under atmospheric conditions [19,20]. Reduction of the
Fe(III)-Bm (1:1) complex by adding 2-mercaptoethanol in
the presence of PBN gave the ESR spectrum shown in Fig.
2A. This signal is essentially identical to the PBN-OH adduct,
which is the same as that identi¢ed previously [19]. However,
ESR signals of the Fe(III)-Bm complex, pre-incubated with an
equimolar amount of BLMT for 10 min at room temperature,
were not observed on addition of 2-mercaptoethanol (Fig.
2B).
Hydroxyl radicals are also generated by the xanthine-xan-
thine oxidase reaction system [17]. The ESR spectrum, given
by this system using PBN, is shown in Fig. 2C. This PBN-OH
signal was observed when the system was pre-incubated with
BLMT (data not shown), indicating that BLMT traps neither
hydroxyl radicals nor PBN. These results clearly show that
BLMT inhibits the DNA cleavage which is caused by the
production of hydroxyl radical.
3.2. Immunological properties of BLMT
To generate an anti-BLMT monoclonal antibody, we used
the puri¢ed BLMT (Fig. 1) as an antigen. Eight hybridomas,
which secrete antibodies showing an anti-BLMT activity, were
screened by enzyme-linked immunosorbent assay (ELISA).
The antibody designated No. 925-1 showed the highest activ-
ity among the eight candidates. Western blot analysis reveals
that No. 925-1 strongly reacts with BLMT (Fig. 3B, lanes 1
and 5), but not with Shble protein, BLMA and BLMS, even
when used at 100-fold the concentration used for BLMT (Fig.
3B). BLMT always migrated on Tricine-SDS-PAGE [18] at
about 12 kDa, which is smaller than the molecular size (14
kDa) deduced from the nucleotide sequence. On the other
hand, BLMA always migrated on the same PAGE at 15.5
kDa, which is larger than expected [4]. In addition, an anti-
BLMA monoclonal antibody [4] did not cross-react with
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Fig. 4. Survival curves of E. coli HB101 transformed with the fol-
lowing plasmids. E, pKKtrp ; W, pKKblmTM; a, pKKblmT. The
colony-forming units (CFU) were determined as described in
Section 2.
Fig. 3. Tricine-SDS-PAGE (A) and Western blotting (B) pro¢les of
Bm-binding proteins. A: The proteins were stained with Coomassie
brilliant blue R-250. Lanes: 1, molecular size marker; 2 and 6,
BLMT (2 Wg); 3, Shble protein (2 Wg); 4, BLMA (2 Wg); 5, BLMS
(2 Wg). B: The proteins, Western-blotted using anti-BLMT monoclo-
nal antibody, were stained with Elite ABC Kit. Lanes: 1 and 5,
BLMT (10 ng); 2, Shble protein (1 Wg); 3, BLMA (1 Wg); 4, BLMS
(1 Wg).
Fig. 2. ESR spectra obtained from chemical reduction of Fe(III)-
Bm (A and B) and xanthine-xanthine oxidase reaction (C) using
PBN as a spin trap. A: 0.1 mM Bm-Fe(III) complex and 80 mM
PBN. B: 0.1 mM Fe(III)-Bm complex pre-incubated with 0.1 mM
BLMT and 80 mM PBN. C: 0.5 mM xanthine, xanthine oxdase (25
mU), 0.014 mM EDTA and 80 mM PBN. The scale bars indicate
10 Gauss.
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BLMT (data not shown). We have also shown that a poly-
clonal antibody, raised against Shble protein in rabbit, did not
cross-react with BLMA [4]. These results suggest that BLMT
is immunologically distinct from the other Bm-binding pro-
teins, although they share the same function.
3.3. The ble-mediated Bm resistance is independent of its
survival advantage
In addition to the function of the ble gene product as a Bm
resistance determinant, the protein has been suggested to con-
fer a survival advantage to the host cells, as a result of the
enhancement of the DNA repair system [12,13]. To analyze
the relationship between the ble-mediated Bm resistance and
the survival advantage on the host cell, we created a mutant
ble protein which lacked Bm-resistant activity. The minimum
inhibitory concentration (MIC) of Bm against E. coli carrying
ble was over 250 Wg/ml, whereas the same host transformed
with the plasmid carrying a mutant ble, replacing proline with
leucine at N-terminal amino acid position 7, lost resistance to
Bm (MIC6 4 Wg/ml). Fig. 4 shows that E. coli harboring the
mutant ble exhibited the same survival curve as that harboring
the wild-type ble (Fig. 4). These results suggest that even if the
ble gene product lost Bm resistance activity, it retained the
ability to provide a survival advantage to the host cell.
Fig. 5 shows conservative regions among the alignment of
amino acid sequences of the four proteins. These Bm-binding
proteins share similar physico-chemical properties of a low
isoelectric point and a low molecular weight (14 kDa). Judg-
ing from these characteristics, their encoding genes might be
derived from the same ancestor.
We discovered that BLMT inhibits the generation of hy-
droxyl radical by the Fe(III)-Bm complex in the presence of a
reductant, as a result of its binding to Bm. This result suggests
that the inhibition results in the disappearance of the Bm-
induced DNA breakage and antibacterial activities [23].
Our established anti-BLMT monoclonal antibody showed
speci¢c binding to BLMT. Although BLMT inhibits Bm-in-
duced DNA breakage, restoration of the Bm-induced DNA
breakage was observed when BLMT was pre-incubated with
the anti-BLMT monoclonal antibody (data not shown), sug-
gesting that the antibody-bound BLMT no longer binds the
drug. This result not only exhibits speci¢city of the antibody
to BLMT, but also de¢nitely con¢rms that BLMT is a Bm-
binding protein.
The X-ray crystal structure analysis of the Shble protein
revealed that the N-terminal proline 9 residue may be neces-
sary for arm exchange to form the dimer structure [24,25]. In
fact, the proline residue is conserved in all four Bm-binding
proteins, including BLMT (Fig. 5). Replacement of proline 9
by leucine in BLMA from S. verticillus abolished Bm resist-
ance in E. coli. We con¢rmed that this mutant BLMA lost the
Bm-binding ability due to its forming no dimer structure (our
unpublished data). In the present study we created a mutant
protein in which proline 7 in BLMT was replaced by leucine.
The E. coli cells transformed with the mutant ble lost Bm
resistance. This may be due to the loss of Bm-binding ability
of BLMT like the mutant BLMA. The ble-mediated Bm re-
sistance in E. coli has been demonstrated to require the ex-
pression of host genes, such as aidC and polA, which induce
the DNA repair system [26]. Several advantages to E. coli
carrying ble are proposed to be associated with the ble-in-
duced enhancement of the DNA repair system, which in-
creases the repair of spontaneous DNA lesions. The present
study showed that the survival of E. coli carrying the mutant
ble lacking Bm resistance was the same as that of E. coli
carrying the wild-type ble, indicating that even the mutant
ble can induce the DNA repair system of the host cells.
The present study suggests that BLMT is a bifunctional
protein, in which the two functions are independent. Judging
from the result of the mutant BLMA, the mutant BLMT,
created by replacing proline with leucine, might also not
form a dimer structure. This suggests that the mutant protein
is likely to abolish the function as the Bm resistance determi-
nant. It is of interest that the monomeric BLMT, which does
not confer Bm resistance, can improve the survival advantage
to the host cell as a result of a putative enhancement of the
DNA repair system. To elucidate the unique biological func-
tion of BLMT, crystallization and X-ray di¡raction studies of
the BLMT protein are in process. These results will be sub-
mitted elsewhere.
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Fig. 5. Alignment of the amino acid sequences of BLMA, Shble protein, BLMS and BLMT. The boxes indicate conserved amino acids.
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